Retatrutide vs. Tirzepatide vs. Semaglutide: The Triple-Agonist Preview
Prices verified May 2026 · Updated for mid-2026
⚡ TL;DR — OUR VERDICT
Retatrutide's 24% weight loss in Phase 2 makes it potentially the most effective weight loss drug ever tested. But it's not approved yet, and Phase 3 results are still being collected. Don't wait for retatrutide — start treatment now with available options. If it's approved, switching will be straightforward.
What Is Retatrutide?
Retatrutide is Eli Lilly's triple-agonist: it activates GLP-1, GIP, and glucagon receptors simultaneously. While tirzepatide pulls two levers (GLP-1 + GIP), retatrutide pulls three. The addition of glucagon receptor agonism is theorized to increase energy expenditure (calorie burning) on top of appetite suppression — a mechanism no current obesity drug offers.
The Phase 2 Numbers
| Drug | Mechanism | Weight Loss | Trial Phase |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | ~15% | Approved |
| Tirzepatide (Zepbound) | GLP-1 + GIP | ~21% | Approved |
| Retatrutide | GLP-1 + GIP + Glucagon | ~24% | Phase 3 (2026) |
A 24% average weight loss at 48 weeks is unprecedented. For a 250-pound person, that's 60 pounds. Individual high responders in the trial lost over 30% of their body weight.
What's Left to Prove
Phase 2 trials are small (about 300 participants for the obesity cohort). Phase 3 trials enroll thousands and are designed to confirm both efficacy and safety at scale. Lilly has seven Phase 3 trials underway, covering obesity, type 2 diabetes, sleep apnea, and metabolic syndrome. These trials are expected to complete throughout 2026.
FDA filing could happen as early as late 2026 or early 2027, with potential approval in 2027–2028.
Why Not Wait?
- Approval timeline is uncertain: Phase 3 data could show safety signals that delay or prevent approval
- Obesity is progressive: Every month of untreated excess weight has cardiovascular and metabolic consequences
- Current drugs work: 15–21% weight loss with semaglutide or tirzepatide is clinically transformative
- Switching is easy: If retatrutide is approved, you can switch from your current medication. Starting treatment now doesn't lock you out of future options
What Retatrutide Means for Current Medications
If approved at 24% efficacy, retatrutide would become the clear frontline treatment for severe obesity (BMI ≥ 40). Current medications would likely remain first-line for moderate obesity and become "step-down" options for maintenance after retatrutide-driven weight loss.
The compounded market would eventually incorporate retatrutide once it reaches shortage or compounding eligibility conditions — but that's years away from approval.
Start Treatment Now
Embody
$149 first month
Injectable compounded semaglutide $149 first month. Switch to newer drugs when available.
Compare →Paid link · Compounded medications are not FDA-approved
Sesame Care
From $29/visit
Brand-name Zepbound and Foundayo. Transition to retatrutide if/when approved.
Compare →Paid link · Compounded medications are not FDA-approved
Compare All 26 Providers
Side-by-side pricing, formats, and what's included.
See the Full Comparison →